Market Analysis: Global Dystonia Drug Market
Global dystonia drug market is expected to grow at a substantial CAGR in the forecast period of 2019-2026. The emergence of drugs used in the treatment of neurological and metabolic disorders, development of newer technologies and vulnerable dystonia disease patients are the key factors enhancing the market growth.
Market Definition: Global Dystonia Drug Market
Dystonia is neurological movement disorder characterized by involuntary uncontrollable muscle contraction that results in slow repetitive movements or irregular postures. The irregular contraction causes muscles to twist involuntarily and affect different parts of the body. The person with dystonia may experience dragging leg, cramps in the foot, involuntary pulling of muscles of neck, uncontrollable blinking and difficulties in speech.
According to The Dystonia Society 2016, it was estimated over 70,000 patients were diagnosed dystonia in the United Kingdom. Growing number of incidence cases, accelerating demand of novel therapies and uses of drugs used in treatment of metabolic disorders are the key drivers for market growth.
- Increase in prevalence rate of dystonia disorders worldwide
- Rising awareness about dystonia therapy and technological advancement is driving the growth of market
- Increase in the rate of R&D initiatives is driving dystonia therapeutics market
- Effective treatment is either unavailable or unaffordable
- Patent expiry from many companies and introduction of generic drugs of branded version is expected to restrain the growth if the market
- Inadequate knowledge about dystonia in some developing countries
Segmentation: Global Dystonia Drug Market
- By Classification Type
- By Age Type
- Childhood onset – 0 to age 12
- Adolescent onset – age 13 to 20
- Adult onset – older than age 20
- By Body Part Type
- Spasmodic dysphonia
- Lower limb dystonia
- Focal dystonia
- Cervical dystonia
- By Causes Type
- Dopa-responsive dystonia
- Paroxysmal dyskinesias
- Rapid-onset dystonia Parkinsonism
- Heredodegenerative Dystonia
- By Age Type
By Therapy Type
- Physical therapy
- Speech therapy
- Sensory manoeuvres
By Treatment Type
- Deep brain stimulation
- Selective denervation surgery
- Anterior cervical rhizotomy
By Mechanism of Class Type
- Dopaminergic Agents
- Muscle relaxants
- Dopamine-depleting agents
By Route of administration
By End users
- Specialty Clinics
- North America
- South America
- Rest of South America
- United Kingdom
- Rest of Europe
- South Korea
- Rest of Asia Pacific
- Middle East & Africa
- South Africa
- Saudi Arabia
- United Arab Emirates
- Rest of Middle East & Africa
Key Developments in the Market
- In November 2017, Revance Therapeutics, Inc has received Orphan Drug designation from the US FDA for DaxibotulinumtoxinA for Injection (RT002) for the treatment of cervical dystonia. If approved, it will be the potential commercial milestone for Revance Therapeutics, Inc.
- In March 2017, Ipsen Pharma received approval in Canada from the Health Canada for Dysport therapeutic (abobotulinumtoxina) for the treatment of cervical dystonia as well as for adult upper limb spasticity. This approval makes new treatment option available to patients with cervical dystonia in need throughout the Canada
Competitive Analysis: Global Dystonia Drug Market
Global dystonia drug market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of dystonia drug market for Global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.
Key Market Players: Global Dystonia Drug Market
Few of the major competitors currently working in the dystonia drug market are Pfizer Inc, Novartis AG, Sanofi, Merck & Co, Aspen Holdings, China Shineway Pharmaceutical Group Limited, Boston Scientific Corporation, Ipsen Pharma, Revance Therapeutics, Inc, Merz Pharma, US WorldMeds, LLC, Medytox, Allergan, Taro Pharmaceutical Industries Ltd, Mentor Worldwide LLC, Eisai Co., Ltd and few among others.
Research Methodology: Global Dystonia Drug Market
Data collection and base year analysis is done using data collection modules with large sample sizes. The market data is analyzed and forecasted using market statistical and coherent models. Also market share analysis and key trend analysis are the major success factors in the market report. To know more please request an analyst call or can drop down your enquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, other data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, Top to Bottom Analysis and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
Demand Side: Doctors, Surgeons, Medical Consultants, Nurses, Hospital Buyers, Group Purchasing Organizations, Associations, Insurers, Medical Payers, Healthcare Authorities, Universities, Technological Writers, Scientists, Promoters, and Investors among others.
Supply Side: Product Managers, Marketing Managers, C-Level Executives, Distributors, Market Intelligence, and Regulatory Affairs Managers among others.
Reasons to Purchase this Report
- Current and future of global dystonia drug market outlook in the developed and emerging markets
- The segment that is expected to dominate the market as well as the segment which holds highest CAGR in the forecast period
- Regions/Countries that are expected to witness the fastest growth rates during the forecast period
- The latest developments, market shares, and strategies that are employed by the major market players